| Peer Reviewed: Obesity Among High School Students in the United States: Risk Factors and Their Population Attributable Fraction EY Hu, S Ramachandran, K Bhattacharya, S Nunna Preventing chronic disease 15, 2018 | 39 | 2018 |
| Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population … SJ Baum, PB Rane, S Nunna, M Habib, K Philip, K Sun, X Wang, ... American journal of preventive cardiology 6, 100177, 2021 | 12 | 2021 |
| Impact of lurasidone and other antipsychotics on body weight: real-world, retrospective, comparative study of 15,323 adults with schizophrenia I Pochiero, F Calisti, A Comandini, A Del Vecchio, I Costamagna, ... International Journal of General Medicine, 4081-4094, 2021 | 6 | 2021 |
| Low‐density lipoprotein cholesterol lowering in real‐world patients treated with evolocumab NR Desai, RL Wade, P Xiang, L Pinto, S Nunna, X Wang, J Exter, ... Clinical cardiology 44 (5), 715-722, 2021 | 5 | 2021 |
| Demographic and clinical characteristics of patients prescribed proprotein convertase subtilisin/kexin type 9 inhibitor therapy and patients whose current lipid-lowering … SJ Baum, RL Wade, P Xiang, J Arellano, C Cerezo Olmos, S Nunna, ... Therapeutics and Clinical Risk Management, 1325-1332, 2019 | 5 | 2019 |
| US cost burden of relapsed refractory multiple myeloma during third and later lines of treatment G Felber, CC Chen, J Willson, C Bell, E Simard, S Nunna, C Dharmani, ... Blood 134, 4725, 2019 | 3 | 2019 |
| Incidence of corneal adverse events in patients with multiple myeloma and their clinical and economic impact: A real-world retrospective cohort study F Wang, L Sansbury, S Ferrante, EM Maiese, J Willson, CC Chen, ... Journal of Medical Economics 25 (1), 182-192, 2022 | 2 | 2022 |
| Patient characteristics and acute cardiovascular event rates among patients with very high‐risk and non‐very high‐risk atherosclerotic cardiovascular disease GC Fonarow, MN Kosiborod, PB Rane, S Nunna, G Villa, M Habib, ... Clinical Cardiology 44 (10), 1457-1466, 2021 | 2 | 2021 |
| Confirming the timing of phase-based costing in oncology studies: a case example in advanced melanoma M Atkins, AD Coutinho, S Nunna, K Gupte-Singh, M Eaddy Journal of Medical Economics 21 (2), 212-217, 2018 | 2 | 2018 |
| Tolvaptan and kidney function decline in older individuals with autosomal dominant polycystic kidney disease: a pooled analysis of randomized clinical trials and observational … FT Chebib, X Zhou, D Garbinsky, E Davenport, S Nunna, D Oberdhan, ... Kidney Medicine 5 (6), 100639, 2023 | 1 | 2023 |
| Lipid lowering therapy patterns and the risk of cardiovascular events in the 1-year after acute myocardial infarction in United Arab Emirates L Pinto, M Farghaly, S Nunna, B Chickballapur Ramachandrachar, ... Plos one 17 (9), e0268709, 2022 | 1 | 2022 |
| Pooled Data Analysis of the Long-Term Effect of Tolvaptan in Patients Between 56 and 65 Years With Autosomal Dominant Polycystic Kidney Disease (ADPKD) F Chebib, X Zhou, D Garbinsky, E Davenport, S Nunna, D Oberdhan, ... AMERICAN JOURNAL OF KIDNEY DISEASES 79 (4), S83-S83, 2022 | 1 | 2022 |
| Impact of social determinants of health (SDOH) and specialist care on healthcare resource utilization (HRU) and costs in autosomal dominant polycystic kidney disease (ADPKD) K Kilgore, K Pareja, C Teigland, I Mohammadi, L Frank, B Agatep, ... AMERICAN JOURNAL OF KIDNEY DISEASES 79 (4), S36-S36, 2022 | 1 | 2022 |
| Number needed to treat (NNT) analysis of patients in CheckMate 649 (CM 649): Nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric … R Sugarman, S Nunna, KA Betts, X Nie, H Nguyen Journal of Clinical Oncology 40 (4_suppl), 307-307, 2022 | 1 | 2022 |
| Lipid lowering treatment patterns and risk of subsequent cardiovascular outcomes among patients initially rejected for pcsk9 inhibitor therapy N Desai, P Rane, S Nunna, CC Chen, J Exter, M Habib, Z Zhou, R Wade Journal of Clinical Lipidology 14 (4), 599-600, 2020 | 1 | 2020 |
| Geographic variation in LDL-C levels and lipid lowering therapy use in patients with atherosclerotic cardiovascular disease SJ Baum, S Nunna, P Rane, K Philip, M Habib, X Wang, R Wade Journal of Clinical Lipidology 13 (3), e32-e33, 2019 | 1 | 2019 |
| WCN24-1268 End-Stage Kidney Disease (ESKD) and Chronic Kidney Disease (CKD) Progression among a Hispanic/Latino Population with Primary Immunoglobulin A Nephropathy (IgAN) J Sim, N Cannizzaro, Q Chen, S Nunna, AW Fernandes, C Pinto, ... Kidney International Reports 9 (4), S157-S158, 2024 | | 2024 |
| Tolvaptan and Number Needed to Harm in Autosomal Dominant Polycystic Kidney Disease KA Betts, S Nunna, R Kumar, X Nie, AW Fernandes Kidney Medicine, 2024 | | 2024 |
| Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis M Lioudis, X Zhou, E Davenport, S Nunna, HB Krasa, D Oberdhan, ... BMC nephrology 24 (1), 182, 2023 | | 2023 |
| POST-MARKETING LIVER SAFETY DATA FROM 4 YEARS OF THE TOLVAPTAN RISK EVALUATION AND MITIGATION STRATEGY (REMS) IN THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE … M Lioudis, S Nunna, V George, R Kumar, AW Fernandes AMERICAN JOURNAL OF KIDNEY DISEASES 81 (4), S101-S101, 2023 | | 2023 |
